Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors

British Journal of Pharmacology

Volumn 157, Issue 8, 2009, Pages 1368-1379

  Xu, Youhua ^a   Zhang, Rongjian ^a   Chen, Jie ^a   Zhang, Qichun ^a   Wang, Juejin ^a   Hu, Jue ^a   Guan, Xiaowei ^a   Jin, Lai ^a   Fu, Hong ^a   Gui, Bo ^a   Guo, Yuanyuan ^a   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CRF1 receptor; CRF2 receptor; Thromboangiitis obliterans; Urocortin; Vasculitis

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTISAUVAGINE 30; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ALPHA; INTERCELLULAR ADHESION MOLECULE 1; LAURATE SODIUM; LAURIC ACID DERIVATIVE; MESSENGER RNA; PROSTAGLANDIN E2; THROMBOXANE B2; UNCLASSIFIED DRUG; UROCORTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD RHEOLOGY; BUERGER DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMORAL ARTERY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; VASCULITIS; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; ARTERITIS; BLOOD COAGULATION; CORTICOTROPIN-RELEASING HORMONE; CYCLOOXYGENASE 2; DINOPROSTONE; INTERCELLULAR ADHESION MOLECULE-1; LAURIC ACIDS; MALE; PEPTIDE FRAGMENTS; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; THROMBOANGIITIS OBLITERANS; THROMBOXANE B2; UROCORTINS;

EID: 70350324904     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00210.x     Document Type: Article

References (54)

1. Agelaki S, Tsatsanis C, Gravanis A, Margioris AN (2002). Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 70: 6068-6074.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Ashida S, Ishihara M, Ogawa H, Abiko Y (1980). Protective effect of ticlopidine onexperimentally induced peripheral arterial occlusive disease in rats. Thromb Res 18: 55-67.
4. Baigent SM (2001). Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides 22: 809-820.
5. Baigent SM, Lowry PJ (2000). mRNA expression profiles for corticotrophin-releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 25: 43-52.
6. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL et al. (2002). Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci U S A 99: 7734-7739.
7. Bamberger CM, Wald M, Bamberger AM, Ergün S, Beil FU, Schulte HM (1998). Human lymphocytes produce urocortin, but not corticotropin-releasing hormone. J Clin Endocrinol Metab 83: 708-711.
8. Brar BK, Chen A, Perrin MH, Vale W (2004). Specificity and regulation of extracellularly regulated Kinase1/2 phosphorylation through Corticotropin- Releasing Factor (CRF) receptors 1 and 2b by the CRF/Urocortin Family of peptides. Endocrinology 145: 1718-1729.
9. Chen DY, Lan JL, Lin FJ, Hsieh TY (2005). Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum 53: 320-327.
10. Cipollone F, Fazia ML (2006). COX-2 and Atherosclerosis. J Cardiovasc Pharmacol 47: S26-S36.
11. Cui XM, Pan L, Cui L, Qi GC, Li ZB (2000). Ultrastructural diagnosis of thromboangiitis obliterans. J Chin Electron Microsc Soc 19: 811-814.
12. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB et al. (1998). Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073.
13. Fekete EM, Zorrilla EP (2007). Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28: 1-27.
14. Fiessinger JN, Schäfer M (1990). Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans: the TAO study. Lancet 335: 555-557.
15. Gando S, Kameue T, Matsuda N, Hayakawa M, Ishitani T, Morimoto Y et al. (2002). Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost 88: 943-949.
16. Gao L, Lu C, Xu C, Tao Y, Cong B, Ni X (2008). Differential regulation of prostaglandin production mediated by CRH receptor type 1 and type 2 in cultured human placental trophoblasts. Endocrinology 149: 2866-2876.
17. Halacheva K, Gulubova MV, Manolova I, Petkov D (2002). Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 104: 177-184.
18. Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL et al. (2008). Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 105: 3939-3944.
19. Inada Y, Ikeda K, Tojo K, Sakamoto M, Takada Y, Tajima N (2009). Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation. Peptides 30: 365-372.
20. Joras M, Poredos P, Fras Z (2006). Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation. Eur J Clin Invest 36: 376-382.
21. Kageyama K, Hanada K, Nigawara T, Moriyama T, Terui K, Sakihara S et al. (2006). Urocortin induces Interleukin-6 gene expression via Cyclooxygenase-2 activity in Aortic Smooth Muscle Cells. Endocrinology 147: 4454-4462.
22. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP (1991). Autocrine or paracrine inflammatory actions of corticotro-pinreleasing hormone in vivo. Science 254: 421-423.
23. Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue KI et al. (2001). Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab 86: 4344-4352.
24. Li X, Hu J, Zhang R, Sun X, Zhang Q, Guan X et al. (2008). Urocortin ameliorates diabetic nephropathy in obese db/db mice. Br J Pharmacol 154: 1025-1034.
25. Murakami T, Sawada K, Taneda K, Hayashi M, Katsuura Y, Tanabe H et al. (1995). Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease. Arzneimittelforschung 45: 991-994.
26. Nakata Y, Ban I, Hirai M, Shionoya S (1976). Onset and clinicopatho-logical course in Burger's disease. Angiology 27: 509-517.
27. Nielubowicz J, Rosnowski A, Pruszynski B, Przetakiewicz Z, Potemkowski A (1980). Natural history of Buerger's disease. J Cardiovasc Surg 21: 529-540.
28. Nizankowski R, Królikowski W, Bielatowicz J, Szczeklik A (1985). Pros-tacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thromb Res 37: 21-28.
29. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T (2000). Induction of Cyclooxygenase-2 by Angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 35: 68-75. (Pubitemid 30054239)
30. Oki Y, Sasano H (2004). Localization and physiological roles of urocortin. Peptides 25: 1745-1749.
31. Okosi A, Brar BK, Chan M, D'Souza L, Smith E, Stephanou A et al. (1998). Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 32: 167-171.
32. Olin JW (2000). Thromboangiitis obliterans (Buerger's disease). N Engl J Med 343: 864-869.
33. Pisarchik A, Slominski A (2004). Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem 271: 2821-2830.
34. Puéchal X, Fiessinger JN (2007). Thromboangiitis obliterans or Buerg-er's disease: challenges for the rheumatologist. Rheumatology 46: 192-199.
35. Quevedo ME, Slominski A, Pinto W, Wei E, Wortsman J (2001). Pleio-tropic effects of corticotropin releasing hormone on normal human skin keratinocytes. In Vitro Cell Dev Biol Anim 37: 50-54.
36. Saruta M, Takahashi K, Suzuki T, Torii A, Kawakami M, Sasano H (2004). Urocortin 1 in colonic mucosa in patients with ulcerative colitis. J Clin Endocrinol Metab 89: 5352-5361.
37. Shirakura S, Higo K, Takeda M, Karasawa A (1994). Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol 65: 93-98.
38. Silver MJ, Smith JB, Ingerman C, Kocsis JJ (1973). Arachidonic acid induced human platelet aggregation and prostaglandin formation. Prostaglandins 4: 863-875.
39. Silver MJ, Hoch W, Kocsis JJ, Ingerman CM, Smith JB (1974). Arachi-donic acid causes sudden death in rabbits. Science 183: 1085-1087.
40. Singh LK, Boucher W, Pang X, Letourneau R, Seretakis D, Green M et al. (1999). Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther 288: 1349-1356.
41. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee KW et al. (2000). Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 58: 1664-1676.
42. Teli T, Markovic D, Hewitt ME, Levine MA, Hillhouse EW, Grammato-poulos DK (2008). Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. Cell Signal 20: 40-49.
43. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E et al. (1998). Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403-413.
44. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P (2004). Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 25: 563-568.
45. Uzuki M, Sasano H, Muramatsu Y, Totsune K, Takahashi K, Oki Y et al. (2001). Urocortin in the synovial tissue of patients with rheumatoid arthritis. Clin Sci 100: 577-589. (Pubitemid 32523309)
46. Vane JR, Bakhle YS, Botting RM (1998). Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120.
47. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S et al. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378: 287-292.
48. Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G et al. (2008). Urocor-tin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26: 359-368.
49. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP (1996). In vivo and in vitro characterization of antalarmin a non-peptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137: 5747-5750.
50. Witkowska AM (2005). Soluble ICAM-1: a marker of vascular inflammation and lifestyle. Cytokine 31: 127-134.
51. Wu Y, Xu Y, Zhou H, Tao J, Li S (2006). Expression of urocortin in rat lung and its effect on pulmonary vascular permeability. J Endocrinol 189: 167-178.
52. Wu Y, Hu J, Zhang R, Zhou C, Xu Y, Guan X et al. (2008). Enhanced intracellular calcium induced by urocortin is involved in degranu-lation of rat lung mast cells. Cell Physiol Biochem 21: 173-182.
53. Wu Y, Zhang R, Zhou C, Xu Y, Guan X, Hu J et al. (2009) Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice. Atherosclerosis 203: 360-370.
54. Yokotani K, Murakami Y, Okada S, Hirata M (2001). Role of brain arachidonic acid cascade on central CRF1 receptor-mediated activation of sympatho-adrenomedullary outflow in rats. Eur J Pharmacol 419: 183-189.